Tocilizumab Plus Methotrexate Brings Remission for Some
Tocilizumab plus methotrexate showed significant clinical improvements in efficacy and safety in patients with moderate to severe rheumatoid arthritis (RA) who had not adequately responded to anti-tumor necrosis factor (anti-TNF) therapy, according to a new study presented at the Annual Congress of the European League Against Rheumatism. Tocilizumab, an anti-interleukin (IL)-6 receptor monoclonal antibody, was demonstrated to be effective irrespective of the number of, or the most recently failed anti-TNF treatments.
After 24 weeks of treatment, 30.1% of patients receiving tocilizumab plus methotrexate, who had active RA despite prior anti-TNF therapy, achieved DAS28 (a measure of disease remission) compared with only 1.6% of those receiving placebo.
Professor Paul Emery of Leeds Teaching Hospital Trust / Leeds University, UK, lead investigator in the trial, said, "Although anti-TNF therapies for RA are well-established, a substantial number of patients are inadequately controlled by these treatments, or become refractory to them. The results of this trial suggest that tocilizumab offers a much needed and effective option for such patients."
This article was adapted from a press release issued by EULAR.